Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.

MLA

Chen, Brian, et al. “Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.” The Oncologist, vol. 24, no. 4, Apr. 2019, pp. 537–48. EBSCOhost, https://doi.org/10.1634/theoncologist.2018-0341.

APA

Chen, B., Nagai, S., Armitage, J. O., Witherspoon, B., Nabhan, C., Godwin, A. C., Yang, Y. T., Kommalapati, A., Tella, S. H., DeAngelis, C., Raisch, D. W., Sartor, O., Hrushesky, W. J., Ray, P. S., Yarnold, P. R., Love, B. L., Norris, L. B., Knopf, K., Bobolts, L., … Bennett, C. L. (2019). Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada. The Oncologist, 24(4), 537–548. https://doi.org/10.1634/theoncologist.2018-0341

Chicago

Chen, Brian, Sumimasa Nagai, James O Armitage, Bartlett Witherspoon, Chadi Nabhan, Ashley C Godwin, Y Tony Yang, et al. 2019. “Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.” The Oncologist 24 (4): 537–48. doi:10.1634/theoncologist.2018-0341.